


Financial Results of the 2nd Quarter for Fiscal Year Ending June 2026

February 13, 2026



(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

*Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.*

FYE June 2026 Q2 YTD Main Points -1

Net sales 71,266 Mil.Yen <Year-on-year +15.9%>
Progressed favorably both Medical and Device Division
due to expanding demand, etc.

- **Medical Division ~Progressed favorably in both Cardiovascular and Non-cardiovascular~**
 - Cardiovascular field: Increased mainly in PCI GW and Penetration catheter in all regions
 - Non-Cardiovascular field: Increased in Peripheral in all regions including U.S. and in Abdominal in all regions excluding China
- **Device Division ~ Increased in both Medical and Industrial Components ~**
 - Increased both Medical and Industrial Components due to the consolidation of Nitta Mold as a subsidiary
 - Medical Components business: Increased in transactions of cardiovascular inspection catheter components for the U.S.
 - Industrial Components business: Increased in overseas leisure-related transactions
- **Impact of exchange rate fluctuation (Yen depreciation) (+1,065 Mil. Yen)**

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2026 Q2 YTD	150.74	175.79	21.15	4.68
FYE June 2025 Q2 YTD	151.00	163.37	21.00	4.39

FYE June 2026 Q2 YTD Main Points -2

Operating profit 24,372 Mil. Yen <YoY +40.1%>

Operating profit increased significantly due to higher sales and the improvement in gross profit margin that exceeded expectations

- **Gross profit: 50,311 Mil.Yen < YoY +21.1% >**
 - Increased due to higher sales and an improvement in gross profit margin (67.6% → 70.6%) driven by productivity improvement
 - The impact of U.S. tariffs was minimal (444 Mil. Yen) due to countermeasures in safety stock at the U.S. subsidiary.
- **Operating profit: 24,372 Mil.Yen <YoY +40.1% >**
 - SGA expenses were overall restrained (YoY +1,784 Mil. Yen, increase rate +7.4%)
 - Increased in sales-related expenses due to strengthen promotional activities mainly in the U.S.
 - Increased in R&D expenses (6,111 Mil.Yen) (YoY +291 Mil.Yen, R&D-to-sales ratio 8.6 %)
 - Increased due to the consolidation of Nitta Mold as a subsidiary
 - Decreased in goodwill amortization, etc. (YoY -777 Mil. Yen)
- **Ordinary profit: 24,143 Mil.Yen <YoY +43.5% >**
 - Non-operating expenses: Decreased in foreign exchange losses (YoY -464 Mil.Yen)
- **Net income attributable to parent company shareholders: 17,214 Mil.Yen <YoY +40.4% >**
 - Extraordinary income: Increased gain on sale of investment securities (YoY +605 Mil.Yen)

Highlights Year-on-Year

	FYE June 2025 Q2 YTD		FYE June 2026 Q2 YTD			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)
Net sales	61,491	100.0	71,266	100.0	+9,775	+15.9
Gross Profit	41,549	67.6	50,311	70.6	+8,761	+21.1
Operating profit	17,395	28.3	24,372	34.2	+6,976	+40.1
Ordinary profit	16,821	27.4	24,143	33.9	+7,321	+43.5
Net income attributable to parent company shareholders	12,261	19.9	17,214	24.2	+4,952	+40.4
EPS (yen)	45.14	–	64.56	–	+19.42	+43.0

(Reference) At the same exchange rate as the previous year			
Amount (Mil.Yen)	Ratio (%)	YoY	
		Changes (Mil.Yen)	Changes (%)
70,200	100.0	+8,709	+14.2
49,750	70.9[*]	+8,200	+19.7
24,061	34.3	+6,666	+38.3

*: Gross profit margin after adjusting for forex impacts other than those related to unrealized profit

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2026 Q2 YTD	150.74	175.79	21.15	4.68
FYE June 2025 Q2 YTD	151.00	163.37	21.00	4.39

Sales by Segment Year-on-year


	FYE June 2025 Q2 YTD		FYE June 2026 Q2 YTD			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	55,763	90.7	62,665	87.9	+6,902	+12.4
Device	5,727	9.3	8,600	12.1	+2,872	+50.2
Total amount	61,491	100.0	71,266	100.0	+9,775	+15.9

(Reference)


Medical Field	59,551	96.8	68,085	95.5	+8,533	+14.3
Device Field	1,940	3.2	3,181	4.5	+1,241	+64.0

Earnings Performance by Segment

Net sales




Operating profit




Attribution Analysis of Operating profit – 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating profit – 2

(Exchange Rate Fluctuations Excluded)



Per Segment by Medical Division (by Geography-1)



【Net sales (YoY)】 ~ Increased in all regions, overall remained steady~

■ **Japan** : Increased in Non-cardiovascular field

- Cardiovascular field : Although Penetration catheter increased, products for inspection decreased(*), resulting in flat trend
- Non-cardiovascular field : Strong sales of purchased products in Peripheral vascular (Penumbra)

■ **Overseas** : Increased in all regions

- **US**: Performed solidly in brand products business
 - Cardiovascular field : Increased in PCI GW and Penetration catheter
 - Non-cardiovascular field : Increased in Abdominal and Peripheral vascular
- **Europe**: Progressed favorably due to increases in both direct sales and distributor transactions in Western Europe
 - Cardiovascular field : Increased in PCI GW and Penetration catheter
 - Non-cardiovascular : Increased in various areas such as Peripheral vascular, Abdominal vascular and Neurovascular products.
- **China**: Inventory replenishment (forward shipment) due to sales network changes occurred in both previous and current terms, excluding this impact, remained steady
 - Cardiovascular field : Balloon catheter decreased due to termination of transactions*,but PCI GW performed well
 - Non-cardiovascular field : Decreased in Neurovascular and Abdominal products
(Initial inventory building due to the change of sales channel occurred in previous the term)
- **Other**: Progressed well mainly in Asia
 - Cardiovascular field : Increased in Penetration catheters mainly in Asia
 - Non-cardiovascular field : Increased Peripheral/ Abdominal vascular products mainly in Asia

【Operating profit】 Operating profit increased in proportion to sales


(* Discontinuation of low-profit products)

Per Segment by Medical Division (by Geography-2)

(Mil. Yen)		FYE June 2025 Q2 YTD	FYE June 2026 Q2 YTD	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	151.00	150.74	- 0.26	- 0.2
	EURO	163.37	175.79	+12.42	+7.6
	CNY	21.00	21.15	+0.15	+0.7
Total sales		55,763	62,665	+6,902	+12.4
Japan		7,866	8,307	+440	+5.6
Overseas		47,897	54,358	+6,461	+13.5
US		11,130	12,309	+1,178	+10.6
Europe		11,555	13,918	+2,363	+20.5
China		16,546	18,976	+2,429	+14.7
Other		8,664	9,153	+489	+5.7
Operating profit		18,518	23,948	+5,430	+29.3

Per Segment by Medical Division (by Treatment-1)

【Net sales (YoY)】



OEM
+1.3%

Cardiovascular

Japan : Although Penetration catheter increased, products for inspection decreased(*), resulting flat trend

Non-Cardiovascular
+18.9%

Overseas : Increased in all regions

- U.S.: Increased in PCI GW and Penetration catheter
- Europe: Increased in PCI GW and Penetration catheter, and decreased in Guiding catheters(*)
- China: PCI GW performed well while balloon catheter decreased due to termination of transactions
- Other: Increased in Penetration catheters, and decreased part of products for inspection (*)

(* Discontinuation of low-profit products)

Non-Cardiovascular

Cardiovascular
+11.9%

Japan : Strong sales of purchased products in Peripheral vascular (Penumbra)

Overseas : Increased in the U.S., Europe and other regions

- U.S.: Increased in Abdominal and Peripheral vascular
- Europe :Increased in each areas such as Peripheral, Abdominal vascular and Neurovascular
- China : Decreased in Neuro and Abdominal vascular products
- Other : Increased Peripheral and in Abdominal vascular products mainly in Asia

OEM


Japan : Decreased transactions due to business partner trends

Overseas : Increased in contract development transactions

Per Segment by Medical Division (by Treatment-2)

(Mil. Yen)		FYE June 2025 Q2 YTD	FYE June 2026 Q2 YTD	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	151.00	150.74	- 0.26	- 0.2
	EURO	163.37	175.49	+12.42	+7.6
	CNY	21.00	21.15	+0.15	+0.7
Total sales		55,763	62,665	+6,902	+12.4
	Japan	7,866	8,307	+440	+5.6
	Overseas	47,897	54,358	+6,461	+13.5
Cardiovascular		42,390	47,450	+5,059	+11.9
	Japan	4,282	4,247	- 35	- 0.8
	Overseas	38,107	43,202	+5,095	+13.4
Non-Cardiovascular		9,506	11,299	+1,792	+18.9
	Japan	2,701	3,246	+545	+20.2
	Overseas	6,805	8,052	+1,246	+18.3
OEM		3,866	3,916	+50	+1.3
	Japan	882	813	- 68	- 7.8
	Overseas	2,984	3,103	+118	+4.0

Per Segment by Device Division-1



【Net sales (YoY)】

Increased in both Medical components and Industrial Components Even excluding the consolidation of Nitta Mold as a subsidiary (+1,427 Mil. Yen) , results remained strong

Medical Component

- Japan : Increased due to the consolidation of Nitta Mold as a subsidiary
- Overseas : Increased transactions of cardiovascular inspection catheter components for the U.S.

Industrial Component

- Japan : Increased due to the consolidation of Nitta Mold as a subsidiary
- Overseas : Increased leisure-related transactions and due to the consolidation of Nitta Mold as a subsidiary

【Operating profit】

Increased due to growth in external sales and intersegment transaction

Per Segment by Device Division-2

(Mil. Yen)		FYE June 2025 Q2 YTD	FYE June 2026 Q2 YTD	(Increase due to the consolidation of Nitta Mold as a subsidiary) A	YoY		YoY excluding the impact of A	
					Changes	Changes (%)	Changes	Changes (%)
Exchange rate (Yen)	USD	151.00	150.74	-	- 0.26	- 0.2	-	-
Total sales		5,727	8,600	1,427	+2,872	+50.2	+1,445	+25.2
Japan		1,396	1,927	605	+531	+38.1	- 73	- 5.3
Overseas		4,331	6,672	822	+2,341	+54.1	+1,518	+35.1
Medical Components		3,787	5,419	440	+1,631	+43.1	+1,191	+31.5
Japan		513	954	413	+441	+86.0	+27	+5.4
Overseas		3,274	4,464	26	+1,190	+36.4	+1,164	+35.6
Industrial Components		1,940	3,181	987	+1,241	+64.0	+253	+13.1
Japan		882	973	191	+90	+10.3	- 100	- 11.4
Overseas		1,057	2,208	796	+1,150	+108.9	+354	+33.5
Operating profit		2,457	4,392	193	+1,934	+78.7	+1,741	+70.8
(Reference) Intersegment sales		7,288	8,321	-	+1,032	+14.2	+1,032	+14.2


Reference: P/L

	FYE June 2025 Q2 YTD		FYE June 2026 Q2 YTD			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Net sales	61,491	100.0	71,266	100.0	+9,775	•Both Medical Division and Device Division performed well
Cost of sales	19,941	32.4	20,955	29.4	+1,013	
Gross profit	41,549	67.6	50,311	70.6	+8,761	•Increase in proportion to increasing sales and gross profit margin
SGA	24,154	39.3	25,939	36.4	+1,784	•Increase in expenses related to sales and R&D
Operating profit	17,395	28.3	24,372	34.2	+6,976	
Non-operating income	442	0.7	356	0.5	- 85	
Non-operating expense	1,016	1.7	585	0.8	- 430	•Decrease in foreign exchange losses
Ordinary profit	16,821	27.4	24,143	33.9	+7,321	
Extraordinary income	123	0.2	629	0.9	+505	•Increase in gain on sale of investment securities
Extraordinary loss	-	-	6	0.0	+6	
Net income attributable to parent company shareholders	12,261	19.9	17,214	24.2	+4,952	
Comprehensive income	12,501	20.3	24,378	34.2	+11,877	

Reference: B/S

		FYE June 2025 Results		FYE June 2026 Q2 YTD			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	103,359	53.5	104,558	53.4	+1,198	Inventories +1,827 Cash and deposits -700
	Fixed assets	89,827	46.5	91,311	46.6	+1,483	Tangible fixed assets +1,794
Total assets		193,187	100.0	195,870	100.0	+2,682	
Liabilities	Current liabilities	27,856	14.4	22,359	11.4	- 5,496	Income taxes payables +700 Provision for bonuses -1,128 Other -5,309
	Fixed liabilities	13,976	7.2	14,838	7.6	+861	Long-term borrowings -1,187 Other +1,653
Total liabilities		41,833	21.7	37,198	19.0	- 4,635	
Total net assets		151,354	78.3	158,671	81.0	+7,317	Foreign currency translation adjustment +6,876 Treasury shares +4,434 Retained earnings -1,373 Capital surplus -2,907
Total liabilities & net assets		193,187	100.0	195,870	100.0	+2,682	

Reference: C/F



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

[IR contact]

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-56-1851

URL <https://www.asahi-intecc.co.jp/en>